Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease.

Cancer research - 1 Sept 2009

Nguyen Truc, Vacek Pamela M, O'Neill Patrick, Colletti Richard B, Finette Barry A

Abstract excerpt

The thiopurines azathioprine and 6-mercaptopurine (6-MP) are effective immune modulators and cytotoxic agents extensively used in the treatment of autoimmune diseases, graft rejection, and cancer. There is compelling epidemiologic evidence that thiopurine treatment increases the risk for a variety of tumors by mechanisms that are unclear. We investigated the in vivo mutagenicity of long-term thiopurine treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azathioprine
Share to Carcinogens
Share to Colitis, Ulcerative

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypoxanthine Phosphoribosyltransferase

Share to Immunosuppressive Agents

Share to Mercaptopurine

Share to Mutagenicity Tests

Share to Mutagens

Source

Open in PubMed Open full text

Identifiers

PMID: 19706768
DOI: 10.1158/0008-5472.CAN-09-0451
PMCID: PMC2749269

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease.PMID 19706768Read ↗

Thiopurines, DNA damage, DNA repair and therapy-related cancerSemantic proximity Read ↗

Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT.Semantic proximity Read ↗

Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.Semantic proximity Read ↗

Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug MonitoringSemantic proximity Read ↗

AN EPIDEMIOLOGICAL STUDY OF THIOPURINE-METHYLTRANSFERASE VARIANTS IN A CROATIAN INFLAMMATORY BOWEL DISEASE PATIENT COHORT.Semantic proximity Read ↗

Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel diseaseSemantic proximity Read ↗

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.Semantic proximity Read ↗

Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel diseaseSemantic proximity Read ↗

Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.Semantic proximity Read ↗

Implications of tioguanine dosing in IBD patients with a TPMT deficiencySemantic proximity Read ↗

Effective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of Azathioprine.Semantic proximity Read ↗

Pharmacogenetics of Thiopurines in Inflammatory Bowel DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.